| Title |
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial
|
|---|---|
| Published in |
Trials, July 2020
|
| DOI | 10.1186/s13063-020-04548-z |
| Pubmed ID | |
| Authors |
Keisha Smith, Amy Pace, Stephan Ortiz, Shamsah Kazani, Scott Rottinghaus |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 290 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 290 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 38 | 13% |
| Researcher | 30 | 10% |
| Other | 25 | 9% |
| Student > Master | 24 | 8% |
| Student > Ph. D. Student | 14 | 5% |
| Other | 57 | 20% |
| Unknown | 102 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 86 | 30% |
| Nursing and Health Professions | 24 | 8% |
| Biochemistry, Genetics and Molecular Biology | 13 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 3% |
| Psychology | 6 | 2% |
| Other | 40 | 14% |
| Unknown | 112 | 39% |